INCB086550

INCB086550
Clinical data
Drug class	PD-L1 inhibitor
Identifiers
	IUPAC name (3R)-1-[[7-cyano-2-[3-[3-[[3-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-1,7-naphthyridin-8-yl]amino]-2-methylphenyl]-2-methylphenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-3-carboxylic acid;
CAS Number	2230911-59-6;
PubChem CID	135146787;
DrugBank	DB18901;
ChemSpider	114934734;
UNII	T8B91S15VF;
ChEMBL	ChEMBL5401026;
Chemical and physical data
Formula	C41H39N7O4
Molar mass	693.808 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC=C1C2=NC3=CC(=CC(=C3O2)C#N)CN4CC[C@H](C4)C(=O)O)C5=C(C(=CC=C5)NC6=NC=CC7=CC(=CN=C76)CN8CC[C@H](C8)O)C;
	InChI InChI=1S/C41H39N7O4/c1-24-32(5-3-7-34(24)40-46-36-17-26(15-30(18-42)38(36)52-40)20-47-13-10-29(22-47)41(50)51)33-6-4-8-35(25(33)2)45-39-37-28(9-12-43-39)16-27(19-44-37)21-48-14-11-31(49)23-48/h3-9,12,15-17,19,29,31,49H,10-11,13-14,20-23H2,1-2H3,(H,43,45)(H,50,51)/t29-,31-/m1/s1; Key:QARLNMDDSQMINK-BVRKHOPBSA-N;

INCB086550 is a drug that is a small-molecule inhibitor of programmed death-ligand 1 (PD-L1). A number of antibodies against this target are already in clinical use for cancer treatment, but few small molecule drugs are known. INCB086550 enhances the T-lymphocyte mediated immune response against cancers which express PD-L1, and induces cytokine production. It has been researched for the treatment of cancers such as breast cancer and colorectal cancer.^[1]^[2]^[3]^[4]

References

^ Koblish HK, Wu L, Wang LS, Liu PC, Wynn R, Rios-Doria J, et al. (June 2022). "Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor". Cancer Discovery. 12 (6): 1482–1499. doi:10.1158/2159-8290.CD-21-1156. PMC 9394386. PMID 35254416.
^ Xiang H, Tu B, Feng X, Chen L, Huang Y (April 2025). "Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer". Anti-Cancer Drugs. 36 (4): 280–289. doi:10.1097/CAD.0000000000001685. PMC 11884794. PMID 39774369.
^ Slota A, Golebiowska-Mendroch K, Kocik-Krol J, Musielak B, Stec M, Weglarczyk K, et al. (July 2025). "Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy". ACS Medicinal Chemistry Letters. 16 (7): 1359–1364. doi:10.1021/acsmedchemlett.5c00245. PMC 12257390. PMID 40666457.
^ Wang J, Yu S, Qian L, Wu Y, Zhang W, Awadasseid A (January 2026). "Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects". ChemMedChem. 21 (1) e202500738. doi:10.1002/cmdc.202500738. PMID 41275334.

[1] Koblish HK, Wu L, Wang LS, Liu PC, Wynn R, Rios-Doria J, et al. (June 2022). "Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor". Cancer Discovery. 12 (6): 1482–1499. doi:10.1158/2159-8290.CD-21-1156. PMC 9394386. PMID 35254416.

[2] Xiang H, Tu B, Feng X, Chen L, Huang Y (April 2025). "Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer". Anti-Cancer Drugs. 36 (4): 280–289. doi:10.1097/CAD.0000000000001685. PMC 11884794. PMID 39774369.

[3] Slota A, Golebiowska-Mendroch K, Kocik-Krol J, Musielak B, Stec M, Weglarczyk K, et al. (July 2025). "Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy". ACS Medicinal Chemistry Letters. 16 (7): 1359–1364. doi:10.1021/acsmedchemlett.5c00245. PMC 12257390. PMID 40666457.

[4] Wang J, Yu S, Qian L, Wu Y, Zhang W, Awadasseid A (January 2026). "Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects". ChemMedChem. 21 (1) e202500738. doi:10.1002/cmdc.202500738. PMID 41275334.

[1]

[2]

[3]

[4]